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Abstract Small fibre neuropathy (SFN) has been dem-
onstrated in sarcoidosis. However, a systematic analysis
of neuropathic pain and autonomic symptoms, key features
of SFN, has not been performed. Clinimetric evaluation of
pain and autonomic symptoms using the neuropathic pain
scale (NPS) and the modified Composite Autonomic
Symptoms Scale (mCOMPASS) was used in sarcoidosis
patients for this study. A total of 91 sarcoidosis patients
(n = 23 without SFN symptoms, n = 43 with SFN
symptoms but normal intraepidermal nerve fibre density
(IENFD), n = 25 with SFN symptoms and reduced IEN-
FD) were examined. NPS and mCOMPASS were assessed
twice (reliability studies). Severity of pain was compared
between the subgroups. Correlation between NPS and a
visual analogue pain scale (VAS) was assessed (validity
studies). Healthy controls (n = 105) completed the
mCOMPASS for comparison with patients’ scores. Patients
with sarcoidosis, SFN complaints, and reduced IENFD
demonstrated more severe pain scores on the NPS. The
mCOMPASS differentiated between subjects with and
without SFN symptoms. A significant correlation was
obtained between the NPS and VAS, indicating good
construct validity. Good reliability values were obtained
for all scales. The use of the NPS to evaluate SFN symp-
toms is suggested, as it shows differences between patients
with SFN symptoms with normal or reduced IENFD val-
ues. The mCOMPASS might be used to select patients for
further testing.
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Introduction
Small fibre neuropathy (SFN) is a disorder with selective
involvement of small-calibre myelinated (Ad) and unmy-
elinated (C) nerve fibres, characterised by neuropathic pain
and autonomic symptoms. Diagnosis is usually made on
the basis of clinical features (neuropathic pain, loss of
pinprick and temperature sensation), in combination with
abnormal specialized tests such as the assessment of
intraepidermal nerve fibre density (IENFD) in skin biopsy,
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temperature sensation tests for sensory fibres, and sudo-
motor and cardiovagal testing for autonomic fibres [1].
Pain is a frequent complaint in sarcoidosis, an inflam-
matory multisystem disorder of unknown aetiology which
may involve any part of the nervous system [2], and pain is
related to lower quality of life [3]. We recently demon-
strated SFN to be frequent in sarcoidosis [4]. However,
neither the type or intensity of pain, nor the extent to which
autonomic symptoms may occur in SFN in sarcoidosis
have been studied systematically in this condition. The
current study describes the various aspects of pain and
autonomic symptoms in patients with sarcoidosis using the
neuropathic pain scale (NPS) and a modified Composite
Autonomic Symptoms Scale (mCOMPASS), and assesses
validity and reliability of these outcome measures.
Participants and methods
Participants
One hundred and five healthy volunteers were recruited
from hospital personnel, relatives and friends of patients, at
sports accommodations, and informal meetings for the
elderly. Inclusion criteria were: no pain or other neuro-
logical complaints, no history of alcohol abuse, no diseases
that may cause sensory deficit or pain sensation, and nor-
mal findings at neurological examination [6].
Patients referred to the Maastricht Sarcoidosis Man-
agement Centre, a referral centre for sarcoidosis in The
Netherlands, were screened for eligibility. We included 91
patients in the study. Inclusion criteria were: diagnosis of
sarcoidosis [5], lucid consciousness, no alcohol abuse, no
usage of immunosuppressant drugs in the past 6 months,
no diseases that may cause sensory deficit, and no signs of
central nervous system involvement or large fibre neurop-
athy (no abnormal nerve conduction studies). After inclu-
sion, patients were categorised as either ‘‘no SFN’’, or,
when having SFN symptoms as ‘‘possible SFN’’. A patient
was classified as having SFN symptoms when he or she
reported at least one of the following symptoms, not
otherwise explained: burning pain in extremities, dry
mouth or eyes, changes in sweating, flushes, gastrointesti-
nal dysfunction (constipation, diarrhea), cardiac complaints
(palpitation, dizziness at standing up), urogenital dysfunc-
tion (sexual dysfunction, incontinence) [6].
Scale selection
The NPS was designed to assess distinct pain qualities
associated with neuropathic pain and has been used in
peripheral neurological conditions [7]. The questionnaire
rates ten different aspects of pain on a numerical 0–10
scale. Addressed are intensity and unpleasantness of pain in
general; intensity of sharpness, hotness, dullness, coldness,
skin sensitivity, itching; and intensity of surface and deep
pain.
The horizontal visual analogue pain scale (VAS) is a 10-
cm horizontal line, depicting no pain at the left and worst
pain ever at the right side. Patients mark their pain intensity
at the line. It is considered to reliably assess a patient’s
experience [8].
The original Composite Autonomic Symptom Scale
(COMPASS), validated in patients with autonomic failure
and non-autonomic neuropathies, correlates well with auto-
nomic function tests [9]. Its 73 questions concern different
aspects of the autonomic system: orthostatic intolerance and
reflex syncope, secretomotor, vasomotor, pupillomotor,
urogenital, gastrointestinal, and sleep difficulties.
Translation and modification
The translation of the NPS and mCOMPASS was per-
formed according to the international guidelines [10].
Some domains of the COMPASS were simplified by a
clinimetrician (ISJM), and questions on female sexuality
were added, reflecting an equivalent score for male sex-
uality, resulting in a 65 item modified scale (mCOM-
PASS), with a sum score of 200 for both men and
women.
Skin biopsies
All participants underwent skin biopsy for intraepidermal
nerve fibre density (IENFD) determination according to
European guidelines [11]. Biopsies were taken 10 cm
above the lateral malleolus. Normative values were used to
determine normal versus impaired IENFD findings [6].
Patients were further divided into subgroups according to
the presence of symptoms combined with skin biopsy
results: group A, patients without SFN symptoms; B,
patients with SFN symptoms but normal IENFD; and C,
patients with SFN symptoms and reduced IENFD. We
expected those with both symptoms and reduced IENFD to
be most affected, IENFD being considered an objective
tool to diagnose SFN [11, 12].
Study design and statistics
The study was approved by the medical ethical committee
of the Maastricht University Medical Centre (Central
Committee for Human Related Research, identifier number
p06.0066L/MEC 05-224), in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki.
Informed consent was obtained from all participants prior
to the study. All patients were examined at the Maastricht
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University Medical Centre. Examination took take place in
a comfortable, temperature-controlled room. Question-
naires were provided with written instructions. Healthy
controls were requested to complete the mCOMPASS.
Data collection, entry, and management were performed
using the Teleform automated processing system.
Reliability and validity studies
Patients completed the NPS and mCOMPASS twice,
within 2–4 weeks, without having access to their previous
answers (test–retest reliability; weighted kappa-statistic (j)
measures) [13]. We examined the discriminatory validity
of the NPS in the various patients’ subgroups in relation to
severe pain, defined as a numerical rating score [5 on a
NPS question (Chi-square test). Correlation studies
between the NPS (item pain intensity) and VAS pain scales
were also performed (convergent validity of NPS; Spear-
man’s Rank tests). For the mCOMPASS domains, sub-
groups comparison (one-way ANOVA ? Bonferonni
corrections) was performed. All analyses were performed
using Stata 10.0 for Windows XP.
Results
From October 2006 to July 2008, 105 healthy controls (54
women and 51 men; mean age 45.1 (SD: 14.6; range:
20–79) years), and 91 sarcoidosis patients (41 women, 50
men; age 45.5 (SD: 9.1; range: 27–70) years) were inclu-
ded in the study. The patients with sarcoidosis were sub-
divided into three groups: Group A, patients without SFN
symptoms (n = 23); B, patients with SFN symptoms but
normal IENFD (n = 43); and C, patients with SFN
symptoms and impaired IENFD (n = 25).
In group A, 35% of patients reported severe pain, in
group B 65%, in group C 76%. Not only intensity of pain,
but also various other qualities of pain were significantly
more severe in group C compared to the other subgroups:
‘‘sharpness’’, ‘‘burning’’, ‘‘dullness’’, ‘‘unpleasant pain
sensation’’, and ‘‘intense surface pain’’ (Fig. 1). More
severe pain was also seen for the qualities ‘‘sensitivity of
skin’’ and ‘‘intense deep pain’’ sensations, but the differ-
ences did not reach significance.
Good correlation was obtained between the NPS and
VAS pain scales (NPS (intensity) versus VAS: Spearman’s
rho 0.73).
The mCOMPASS demonstrated higher scores (more
autonomic dysfunction related symptoms) for all domains
and sum scores in the patients with SFN complaints (groups
B and C) compared to group A and healthy controls, but did
not discriminate between the groups B and C (Fig. 2). For
the sexual disorders and syncope domains, no discrimination
between the subgroups and healthy controls was obtained.
Reliability studies showed good test–retest scores for all
domains of the NPS and mCOMPASS (weighted kappa
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Fig. 1 Graphical representation
of several items of the
neuropathic pain scale (NPS) in
patients with sarcoidosis, those
pain qualities with significant
differences between subgroups
are shown (p B 0.04). Bars
show percentage of patients in
the three patient groups with (in
blue) no, (red) minor to
moderate or (green) severe pain.
Group A, sarcoidosis patients
without small fibre neuropathy
(SFN) symptoms. Group B,
sarcoidosis patients with SFN
symptoms, but normal
intraepidermal nerve fibre
density (IENFD). Group C,
sarcoidosis patients with SFN
symptoms and impaired IENFD
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0.60–0.95), except for the mCOMPASS syncope domain
(0.39). The mCOMPASS sum score had a kappa of 0.88.
Discussion
The current study describes the various aspects of pain and
autonomic dysfunction in patients with sarcoidosis using
the NPS and the mCOMPASS. Various neuropathic pain
modalities measured with the NPS were more severe in
patients with SFN complaints and even more so in those
with reduced IENFD values (group C). This tool may be of
use in interventional studies; for example, in evaluating the
efficacy of disease-modifying therapies [14].
As expected, higher mCOMPASS scores were found in
patients with SFN symptoms. Nevertheless, no significant
difference in sum scores was seen between group B and C.
Autonomic nerve fibres are of a different type compared to
the measured ones in skin, and agreement between IENFD
and autonomic deficits varies [15]. Autonomic tests can be
very time consuming though, with a high burden to patients
[16]. Therefore, the use of this scale is suggested to select
patients in whom further testing for SFN might be
warranted.
The NPS correlated well with the VAS, indicating good
construct validity. Both the NPS and the mCOMPASS
demonstrated good test–retest reliability.
There are some methodological issues that should be
addressed. Some caution is requested when interpreting the
results, since the sample sizes of the various subgroups
were relatively small. Also, we did not exclude patients
with painful sarcoidosis related problems such as arthritis.
It may have been difficult for patients to differentiate
between their pain origins, and it might explain why such a
large proportion of patients in group A reports severe pain.
However, the qualities regarded as typically neuropathic
(sharp, hot, superficial pain) were especially more severe in
patients with SFN symptoms and reduced IENFD. Fur-
thermore, the mCOMPASS is a composite ordinal scale
based on the classic test theory, which may have disad-
vantages [17].
In conclusion, the neuropathic pain scale shows differ-
ences between patients with SFN symptoms with normal or
reduced IENFD values, and its use is therefore suggested in
future (interventional) studies of this condition. The pres-
ence of autonomic symptoms as measured by the
mCOMPASS might be used to select patients for further
testing with regard to possible SFN.
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